Hayfin is pleased to announce that it has acquired a minority stake through its Private Equity Solutions (PES) strategy in Novétude Group, a new European healthcare education platform in partnership with Charterhouse Capital Partners. The Group will be built around Novétude Santé, which Charterhouse has owned and grown since 2020. Charterhouse will retain a majority stake in the new platform.
Underpinned by significant industry tailwinds, there is strong sentiment that the Novétude Group is well-positioned to benefit from the large and growing market of European students enrolled in health and welfare studies at private education institutions and an ageing population in Europe, which is expected to drive increased demand for healthcare professionals and services.
Gonzalo Erroz, Managing Director and Co-head of the Private Equity Solutions team at Hayfin, said: “Joining forces with Charterhouse is an exciting development as we continue to invest in exceptional opportunities in the European healthcare education sector. We are proud to contribute to Novétude’s mission of fostering excellence, accessibility and responsibility in professional training, ensuring healthcare specialists are supported throughout every stage of their careers.”
Severin de Mortemart, Managing Director of the Private Equity Solutions team at Hayfin, said: “We are delighted to partner with Charterhouse and to leverage our position as an investor to support Novétude Group through their next stage of development, with the aim of helping to build one of the leading healthcare education platforms in Europe.”
As an active investor in European mid-market companies via single-asset GP-led solutions, Hayfin’s PES strategy benefits from strong alignment of interest with sponsors and management teams that already own, operate and know the target businesses intimately.
Hayfin is pleased to announce that it has acted as Lead Arranger and Agent to global skincare company Crown Laboratories to support its acquisition of Revance Therapeutics (“Revance”; NSDQ; RVNC) with an $850 million first and second lien credit facility.
Hayfin has been a financing partner to Crown Laboratories since 2015, supporting the business both before and during Hildred Capital’s current ownership period. Since then, Hayfin has completed multiple acquisition financings and refinancings in support of Crown Laboratories as the business has scaled.
The acquisition of Revance enables Crown Laboratories to further bolster its best-in-class portfolio and aesthetic skincare products with DAXXIFY and the RHA collection of dermal fillers. As a biotechnology company, Revance will help complement Crown’s existing product portfolio through its innovative aesthetic and therapeutic offerings, enhancing patient outcomes and physician experiences.
Barrett Polan, Managing Director at Hayfin, said: “We are excited to continue our support of long-standing clients, Hildred Capital and Crown Laboratories, as they enter a new and exciting chapter in the Crown Laboratories story with this acquisition. The firm has been on an exceptional growth journey over the past years and has cemented its reputation as one of the foremost providers of aesthetic solutions. The combined portfolio of Crown Laboratories and Revance will enable them to capitalise on future commercial opportunities to grow and we look forward to supporting them on this journey in the future.”
Hayfin invests in the healthcare sector across its private credit strategies and through its specialist healthcare team, which focuses on making strategic investments throughout the capital structure from Hayfin’s various private credit strategies.
Our new report considers how shifting US regulation offers both headwinds and tailwinds for healthcare investors.
The research explores the regulatory landscape and its influence on the competitive positioning of healthcare companies, discussing how:
1) Regulatory forces can act as strong headwinds, particularly for businesses involved in the provision of medical care services or insurance. In our view these sub-sectors are less attractive than other areas of healthcare
2) Some of these same regulatory forces can act as tailwinds for healthcare companies, especially for growth focused technology businesses where long-term success is more dependent on widespread adoption than on payer rates.
3) In these select cases long-term regulatory shifts can create asymmetry to the upside for companies’ return profile.
‘Examining Healthcare’ argues for a nuanced approach to effective capital allocation in the healthcare sector, including a dual focus on limiting disruption from risks that are difficult to quantify and finding opportunities where regulatory shifts can accelerate the adoption of proprietary science or technology.